Issue Date: July 2, 2007
Abbott, Genentech Form Cancer Pact
Abbott Laboratories and Genentech have formed a collaboration for the research, development, and commercialization of two of Abbott's investigational cancer compounds, known as ABT-263 and ABT-869. The small-molecule compounds, discovered by Abbott scientists, are being described as targeted therapies that promise unique approaches to treating cancer. ABT-263 is a Bcl-2 family protein antagonist that restores apoptosis, or cell death, in cancer cells. ABT-869 is a kinase inhibitor that stops tumors from growing by preventing the growth of blood vessels that supply them.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society